Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious beta-secretase inhibitors for the potential treatment of Alzheimer's disease.
Chen, J.J., Liu, Q., Yuan, C., Gore, V., Lopez, P., Ma, V., Amegadzie, A., Qian, W., Judd, T.C., Minatti, A.E., Brown, J., Cheng, Y., Xue, M., Zhong, W., Dineen, T.A., Epstein, O., Human, J., Kreiman, C., Marx, I., Weiss, M.M., Hitchcock, S.A., Powers, T.S., Chen, K., Wen, P.H., Whittington, D.A., Cheng, A.C., Bartberger, M.D., Hickman, D., Werner, J.A., Vargas, H.M., Everds, N.E., Vonderfecht, S.L., Dunn, R.T., Wood, S., Fremeau, R.T., White, R.D., Patel, V.F.
Bioorg.Med.Chem.Lett.
